Investigational drug · Phase 2
Camoteskimab
Also called: APL-9109
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Atopic, Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Camoteskimab"
First trial start
2024
May 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Camoteskimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Atopic
- Dermatitis
- Dermatologic Disease
- Eczema
- Eczema Atopic Dermatitis
- Eczema, Atopic
- Dermatitis, Atopic
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Camoteskimab" as an intervention, largest first.
- A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Apollo Therapeutics LtdIndustry
NCT07599813 · 280 participants (planned) · Start May 28, 2026 · Primary completion Oct 31, 2027
Drug: Camoteskimab; Placebo · For: Atopic Dermatitis; Atopic; Dermatitis and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 85 sites in all
Apollo Therapeutics LtdIndustry
NCT06436183 · 62 participants · Start May 1, 2024 · Primary completion Mar 26, 2025
Drug: Camoteskimab; Placebo · For: Atopic Dermatitis; Atopic; Dermatitis and 4 more
Sites: Phoenix, Arizona; Encinitas, California; Fountain Valley, California · 35 sites in all
Apollo Therapeutics LtdIndustry
NCT04752371 · 5 participants · Start Mar 25, 2021 · Primary completion May 24, 2022
Drug: Camoteskimab (CERC-007, AVTX-007, AEVI-007) · For: Adult Onset Still's Disease
Sites: Gainesville, Florida; Ann Arbor, Michigan; Ghent, Belgium · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.